Thomas King

Mr. King is the Chair of our Board of Directors. He served as Achieve’s interim Executive Chair from August 2024 to June 2025, and as a director since March 2023. Mr. King brings a wealth of knowledge from 40+ years of experience in biopharma leadership positions ranging from large to development-stage companies. He has built, operated and sold multiple public specialty pharmaceutical businesses. Mr. King also serves on the boards of Concentric Analgesics, Inc., and Kinaset Therapeutics, Inc., both clinical stage, privately held biopharmaceutical companies. Previously, Mr. King served on the board of VIVUS, Inc., a publicly traded pharmaceutical company, from May 2017 to December 2020, acting as interim CEO from December 2017 to April 2018 and interim President from April to May 2018. He was President, CEO, and a board member of Alexza Pharmaceuticals, Inc. from June 2003 to August 2016, when it was acquired by Grupo Ferrer, also serving as CFO and Chief Accounting Officer from October 2015 to August 2016. Prior to this, he was President, CEO, and a board member of Cognetix, Inc., a privately held biopharmaceutical company, from September 2002 to April 2003. At Anesta Corporation, a publicly traded pharmaceutical company, he held various senior roles, including President and COO (1995-1997) and President and CEO (1997-2000), and served on the board until its acquisition by Cephalon, Inc. in October 2000. Mr. King received a B.A. in chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business.